The study population included 240,618 patients with overweight or obesity who were prescribed semaglutide or non-GLP1R agonist anti-obesity medications, with the findings replicated in 1,589,855 patients with T2DM
However, this is a relatively new prescription drug, and not enough is known about its long-term safety
Serious hypersensitivity reactions, including anaphylaxis and angioedema have been reported with Wegovy Warnings and Precautions Risk of Thyroid C-Cell Tumors: Patients should be further evaluated if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging Acute Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including semaglutide
semaglutide dose (8 and 16 mg) above approved 2 mg, offers weight loss and modest glycemic benefits, but more gastrointestinal side effects, in type 2 diabetes with overweight/obesity
That is worth being honest with yourself about, and it is still clinically useful
Finally, the samples were prepared for Western blotting analysis by lysing the brain homogenates on ice for 300 minutes in 100 mL of a lysis buffer composed of 120 mM NaCL, 40 mM Tris (pH 8), and 0.1% NP40, followed by centrifugation